1. Introduction {#sec1-molecules-23-01449}
===============

The analysis of druglike chemical space is of outstanding importance in medicinal chemistry. In a recent report, Taylor et al. studied the occurrence of ring frameworks in approved drugs listed in the FDA orange book and established a top 100 of the most frequent ring systems present in small molecule drugs \[[@B1-molecules-23-01449]\]. Although the benzene ring holds the first place in the classification, *N*-heterocycles are ubiquitous. Among them, pyridine is ranked second, piperidine third, piperazine fourth, imidazole seventh and pyrrolidine eighth. Worthy of note, while azetidine itself is not present in the classification, a bicylic ring system incorporating a β-lactam moiety can be found at position nine ([Figure 1](#molecules-23-01449-f001){ref-type="fig"}).

Among the saturated *N*-heterocycles, 4-arylpiperidines, 3-arylpiperidines, 3-arylpyrrolidines and 3-arylazetidines are attractive scaffolds in drug discovery, exhibiting a broad range of biological activities \[[@B2-molecules-23-01449],[@B3-molecules-23-01449],[@B4-molecules-23-01449],[@B5-molecules-23-01449],[@B6-molecules-23-01449],[@B7-molecules-23-01449],[@B8-molecules-23-01449]\]. Due to these interesting properties, numerous methods have been developed to access these aryl substituted *N*-heterocycles, either through ring formation or arylation of cyclic compounds \[[@B9-molecules-23-01449],[@B10-molecules-23-01449],[@B11-molecules-23-01449],[@B12-molecules-23-01449],[@B13-molecules-23-01449]\]. The latter approach could be considered more convergent when molecular diversity is targeted and, particularly, metal-catalyzed cross-couplings involving (pseudo)halogeno-*N*-heterocycles have emerged as a powerful strategy to generate libraries of arylated *N*-heterocycles. In this field, tremendous efforts have been made for the arylation of 4-(pseudo)halopiperidines and numerous metal-catalyzed cross-couplings with organometallic reagents have been reported. Thus, Hiyama \[[@B14-molecules-23-01449],[@B15-molecules-23-01449]\] Suzuki \[[@B16-molecules-23-01449],[@B17-molecules-23-01449],[@B18-molecules-23-01449],[@B19-molecules-23-01449],[@B20-molecules-23-01449]\], Kumada-Corriu \[[@B21-molecules-23-01449],[@B22-molecules-23-01449],[@B23-molecules-23-01449],[@B24-molecules-23-01449]\] and Negishi \[[@B25-molecules-23-01449],[@B26-molecules-23-01449],[@B27-molecules-23-01449],[@B28-molecules-23-01449],[@B29-molecules-23-01449],[@B30-molecules-23-01449],[@B31-molecules-23-01449],[@B32-molecules-23-01449],[@B33-molecules-23-01449]\] couplings have been used to synthesize 4-arylpiperidines using nickel, iron and cobalt catalysts \[[@B34-molecules-23-01449]\]. In addition, nickel-catalyzed reductive coupling involving 4-halopiperidines and (hetero)aryl halides have also been described in the literature \[[@B35-molecules-23-01449],[@B36-molecules-23-01449],[@B37-molecules-23-01449],[@B38-molecules-23-01449],[@B39-molecules-23-01449]\]. In contrast, examples of arylation of 3-halopiperidines are scarce. Knochel et al. recently disclosed a cobalt-catalyzed cross-coupling between 3-iodo-*N*-Boc-piperidine and diarylmanganese reagents to furnish the 3-aryl piperidine in 60% yield \[[@B34-molecules-23-01449]\]. 3-Arylpiperidines could also be formed through nickel catalyzed reductive coupling using aryl bromides \[[@B38-molecules-23-01449],[@B39-molecules-23-01449],[@B40-molecules-23-01449]\]. Similarly, various metal-catalyzed cross-coupling with aryl organometallics \[[@B34-molecules-23-01449],[@B41-molecules-23-01449],[@B42-molecules-23-01449],[@B43-molecules-23-01449],[@B44-molecules-23-01449]\] and metal-catalyzed reductive coupling with aryl halides \[[@B38-molecules-23-01449],[@B45-molecules-23-01449]\] have been used to access 3-arylpyrrolidines and the arylation of 3-haloazetidines has received increasing attention over the past few years. Most of the examples involve nickel-catalyzed Suzuki cross-coupling with aryl boronic acids \[[@B46-molecules-23-01449]\] but 3-arylated azetidines could be obtained from 3-iodoazetidines using iron-catalyzed coupling with aryl Grignard reagents \[[@B23-molecules-23-01449],[@B47-molecules-23-01449]\]. Reductive cross-couplings between 3-iodoazetidine and aryl bromides were also employed to access 3-aryl- azetidines \[[@B33-molecules-23-01449],[@B44-molecules-23-01449],[@B48-molecules-23-01449],[@B49-molecules-23-01449],[@B50-molecules-23-01449]\] ([Scheme 1](#molecules-23-01449-sch001){ref-type="scheme"}).

Despite the variety of reactions existing for the arylation of saturated *N*-heterocycles from halogeno precursors, a unified method allowing the arylation of 4- and 3-halopiperidines, 3-halo-pyrrolidines and 3-haloazetidines was still needed. During the course of our studies toward the development of sustainable methods to access biologically relevant scaffolds, cobalt-catalyzed arylation of saturated halogeno *N*-heterocycles was investigated \[[@B51-molecules-23-01449],[@B52-molecules-23-01449],[@B53-molecules-23-01449]\]. Herein, we report an overview of our work concerning the arylation of 4-iodopiperidines and 3-iodopiperidines, -pyrrolidines and -azetidines. The reactions are efficient, versatile, chemoselective and involve a non-expensive catalytic system ([Scheme 2](#molecules-23-01449-sch002){ref-type="scheme"}) \[[@B54-molecules-23-01449],[@B55-molecules-23-01449]\].

2. Arylation of 4-Halopiperidines {#sec2-molecules-23-01449}
=================================

The reactivity of 4-halopiperidines with aryl Grignard reagents was evaluated to access 4-aryl- piperidines. When *N*-Boc-4-iodo piperidine **1a** was treated with phenylmagnesium bromide in the absence of any metal catalyst, no conversion of the iodide was observed and the starting material was fully recovered ([Table 1](#molecules-23-01449-t001){ref-type="table"}, entry 1). Pleasingly, when Co(acac)~3~ (5 mol %) was introduced in association with *N*,*N*-tetramethylethylenediamine (TMEDA) (6 mol %) as a ligand, the iodo piperidine **1a** was partially transformed to the coupling product **2a** (**1a**/**2a** = 79:21) ([Table 1](#molecules-23-01449-t001){ref-type="table"}, entry 2). The replacement of TMEDA by (*R*,*R*)-tetramethylcyclohexanediamine (TMCD) increased the conversion of **1a** (**1a**/**2a** = 87:13) ([Table 1](#molecules-23-01449-t001){ref-type="table"}, entry 3). Finally, changing Co(acac)~3~ for CoCl~2~ proved beneficial, allowing a full conversion of **1a** into the 4-phenylpiperidine, which could be isolated with a good 81% yield ([Table 1](#molecules-23-01449-t001){ref-type="table"}, entry 4).

With these optimized conditions in hand, the influence of the *N*-protecting group on the cross-coupling outcome was investigated. A *N*-tosyl group was tolerated but the corresponding arylated *N*-tosyl piperidine **2b** was isolated with an inferior yield compared to the *N*-Boc piperidine **2a** (69% *versus* 81%) and two equivalents of the Grignard reagent were required to ensure full conversion of the iodide ([Table 1](#molecules-23-01449-t001){ref-type="table"}, entry 5). With a *N*-benzyl protected iodopiperidine, the coupling proved more difficult, probably due to the coordination of the nitrogen atom to the metal catalyst, and the use of 50 mol % of TMCD was needed to obtain a satisfactory yield in **2c** (66%) ([Table 1](#molecules-23-01449-t001){ref-type="table"}, entry 6). The *N*-Boc 4-bromopiperidine **1b** was less reactive than its iodide counterpart and an increased amount of the Grignard reagent had to be added to reach full conversion ([Table 1](#molecules-23-01449-t001){ref-type="table"}, entry 7). In light of these results, the best conditions to obtain 4-phenylpiperidine involve the use of *N*-Boc 4-iodopiperidine (1 equiv), CoCl~2~ (5 mol %), TMCD (6 mol %) and phenylmagnesium bromide (1.2 equiv) in THF. No syringe pump was needed, the dropwise addition of the Grignard reagent was performed at 0 °C and stirring was continued for 3 h at room temperature. With these conditions in hand, the scope of the arylation was investigated using *N*-Boc iodopiperidines.

A range of aryl magnesium bromides was used in the cross-coupling with *N*-Boc 4-iodo- piperidine **1a**. The electronic properties of the substituents present on the phenyl ring had little influence on the reaction as both electron-donating (*p*-Me, *p*-NMe~2~) and electron-withdrawing (*m*-OMe, *p*-F, *p*-CF~3~) groups were well tolerated. In some cases, the Grignard reagent was prepared as an LiCl complex according to a method reported by Knochel et al. using a catalytic amount of DIBAL-H and a stoichiometric amount of LiCl \[[@B56-molecules-23-01449]\]. These Grignard reagents exhibited similar reactivity to the classical ones under the coupling conditions. The coupling was not sensitive to steric hindrance and *o*-tolylmagnesium bromide reacted smoothly with iodopiperidine **1a** to deliver **2i** in a good 88% yield. The formation of the 4-arylpiperidine **2j** possessing a carbonate substituent on the phenyl ring highlighted the chemoselectivity of the cross-coupling. However, in the presence of a cyano group, the reaction turned sluggish leading to a poor conversion of **1a** (**1a**/**2k** = 70:30) that did not allow the isolation of the corresponding 4-arylpiperidine **2k**. A poisoning of the catalyst by coordination of the nitrile group could account for this limitation. Pleasingly, 3-pyridylmagnesium bromide was efficiently coupled to iodopiperidine **1a**, a decrease in temperature being the key to achieve a high yield in **2l** (96%). Despite its Lewis basicity, the nitrogen atom present on the pyridine moiety does not seem to interfere with the cobalt catalyst ([Scheme 3](#molecules-23-01449-sch003){ref-type="scheme"}).

3. Arylation of 3-Halopiperidines {#sec3-molecules-23-01449}
=================================

As previously mentioned, examples of cross-coupling involving 3-halopiperidines are scarce in the literature. When the previously developed conditions \[CoCl~2~ (5 mol %), TMCD (6 mol %), 0 °C to rt\] were used to perform the coupling between *N*-Boc 3-iodopiperidine **3a** and phenylmagnesium bromide, a full conversion of **3a** was observed, but the desired arylated compound was formed together with several non-identified side products. Lowering the temperature to -10 °C was crucial to allow a selective reaction to occur and, under these conditions, piperidine **4a** was isolated in a good yield (88%). A variety of aryl Grignard reagents differing from the nature of their substituents on the phenyl ring were used with iodopiperidine **3a**, delivering the corresponding 3-arylpiperidine with good to excellent yields (81--94%). The introduction of a pyridyl group at the C3 position was possible, but a moderate yield in the coupling product **4h** was obtained (47%). Increasing the amount of the TMCD ligand (50 mol %) only slightly improved the result (57%) ([Scheme 4](#molecules-23-01449-sch004){ref-type="scheme"}).

The cross-coupling was then used at the key step in a concise synthesis of the antipsychotic (±)-preclamol \[[@B57-molecules-23-01449],[@B58-molecules-23-01449],[@B59-molecules-23-01449]\]. Treatment of the *N*-Boc 3-iodopiperidine **3a** with *m*-methoxyphenylmagnesium bromide in the presence of the CoCl~2~/TMCD catalytic system afforded the 3-arylated piperidine **4i** (88%). After the amine deprotection and reductive amination, the *N*-propylpiperidine was obtained. Finally, the cleavage of the methoxyether under acidic conditions (HBr) delivered (±)-preclamol (33% overall yield over four steps) ([Scheme 5](#molecules-23-01449-sch005){ref-type="scheme"}).

In the literature, the formation of radical species during cobalt-catalyzed cross-coupling has been observed on several occasions \[[@B60-molecules-23-01449],[@B61-molecules-23-01449],[@B62-molecules-23-01449],[@B63-molecules-23-01449]\]. To determine if radical intermediates were present during the arylation of 3-iodopiperidines under our optimized conditions, two radical clocks were synthesized. When the disubstituted 3-iodopiperidine **5a** possessing an *O*-allyl group at C2 was treated with phenylmagnesium bromide in the presence of CoCl~2~ and TMCD, the bicyclic compound **6a** was formed exclusively (81%, dr = 80:20) ([Scheme 6](#molecules-23-01449-sch006){ref-type="scheme"}). This product results from a 5-*exo*-*trig* cyclization prior to the cross-coupling. On the contrary, iodopiperidine **5b**, possessing an additional carbon atom on the C2 pendant chain, was transformed in the 3-phenylpiperidine **6b** resulting from a direct cross-coupling at C3 ([Scheme 6](#molecules-23-01449-sch006){ref-type="scheme"}). These results could suggest that transient radical intermediates were formed during the coupling. The evolution of these species (cyclization then cross-coupling *versus* direct cross-coupling) would depend on the kinetic of the cyclization, the 5-*exo*-*trig* cyclization being approximately 1000 times faster than the 6-*exo*-*trig* cyclization.

4. Arylation of 3-Iodopyrrolidines {#sec4-molecules-23-01449}
==================================

The cross-coupling was then successfully extended to the arylation of 3-iodopyrrolidines. A library of 3-arylpyrrolidines was prepared using a similar catalytic system to the one used for the arylation of iodopiperidines \[CoCl~2~ (5 mol %), TMCD (6 mol %)\]. Whatever the nature of the aryl Grignard reagent, the 3-arylpyrrolidines were obtained with good to excellent yield (74%--93%) ([Scheme 7](#molecules-23-01449-sch007){ref-type="scheme"}) \[[@B56-molecules-23-01449]\].

When iodopyrrolidine **9a** bearing an *O*-allyl chain at C4 was involved in the cross-coupling, the bicyclic compound **10a** was obtained as the sole product with a good yield of 80% (dr = 80:20) ([Scheme 8](#molecules-23-01449-sch008){ref-type="scheme"}). The existence of this 5-*exo*-*trig* cyclization prior to the cross-coupling supports the hypothesis of radical intermediate formation during the reaction.

5. Arylation of 3-Iodoazetidines {#sec5-molecules-23-01449}
================================

Pleasingly, the same catalytic system proved also efficient for the arylation of *N*-Boc 3-iodoazetidine **11a**. A broad range of aryl groups were efficiently introduced at the C3 position of the azetidine. Interestingly, heteroaryl Grignard reagents incorporating either a pyridine or a thiophene moiety were well tolerated, leading to the corresponding azetidines **12i** and **12j** with excellent yields of ca. 90% ([Scheme 9](#molecules-23-01449-sch009){ref-type="scheme"}) \[[@B56-molecules-23-01449]\].

The reactivity of 2,3-disubstituted azetidines was then investigated and a mixture of *cis*- and *trans*-iodoazetidines **13a** (*cis*-**13a**/*trans*-**13a** = 75:25) was treated with phenylmagnesium bromide in the presence of CoCl~2~ and TMCD. The desired arylated product was isolated in 93% yield as a mixture of diastereomers, the *trans* diastereomer being the major product (*cis*-**14a**/*trans*-**14a** = 13:87) ([Scheme 10](#molecules-23-01449-sch010){ref-type="scheme"}). The inversion of the *cis*/*trans* ratio could be due to the formation of a radical intermediate at the C3 position that allowed a diastereoconvergent coupling to occur. However, an epimerization of the organocobalt species resulting from the oxidative addition step could not be excluded.

6. Mechanistic Hypothesis {#sec6-molecules-23-01449}
=========================

Based on literature reports \[[@B61-molecules-23-01449]\] and on our observations, the mechanism depicted in [Scheme 11](#molecules-23-01449-sch011){ref-type="scheme"} can be proposed. At first, a reduction of the Co(II) complex into the active species would be performed by the Grignard reagent to deliver the active catalyst **A** \[Ph~x~Co(n) (*n* = 0, I)\], which oxidation state remains uncertain. A Single Electron Transfer (SET) from this complex to the iodo *N*-heterocycle would deliver a Co(n+1) complex together with the radical intermediate **B**. A subsequent combination of the Co(n+1) complex with radical **B** would led to an organocobalt (n+2) intermediate that would give the product after reductive elimination. A transmetalation between complex **D** and PhMgBr would finally regenerate the active catalyst.

7. Conclusions {#sec7-molecules-23-01449}
==============

In conclusion, an efficient and simple cobalt-catalyzed arylation of saturated iodo-*N*-heterocycles with Grignard reagents was developed. A diversity of *N*-arylated heterocycles was thus prepared from the iodide precursors using a unique catalytic system composed of CoCl~2~ and TMCD. The process is non-expensive, versatile, chemoselective and diastereoselective. The reaction has been used as the key step in a short synthesis of (±)-preclamol. In the future, this cross-coupling could be of high synthetic value to access biologicaly active molecules embedding saturated *N*-heterocycles.
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molecules-23-01449-t001_Table 1

###### 

Cobalt-catalyzed cross-coupling between 4-halopiperidines and phenylmagnesium bromide.

![](molecules-23-01449-i001)

  Entry               1 (X, PG)          \[Co\]        L ^\[a\]^   1/2 ^\[b\]^             2 (yield) ^\[c\]^
  ------------------- ------------------ ------------- ----------- ----------------------- -------------------
  1                   **1a** (I, Boc)    \-            \-          **1a**/**2a** = 100:0   \-
  2                   **1a** (I, Boc)    Co(acac)~3~   TMEDA       **1a**/**2a** = 21:79   n\. d.
  3                   **1a** (I, Boc)    Co(acac)~3~   TMCD        **1a**/**2a** = 13:87   n\. d.
  4                   **1a** (I, Boc)    CoCl~2~       TMCD        **1a**/**2a** = 0:100   **2a** (81%)
  5^\[d\]^            **1b** (I, Ts)     CoCl~2~       TMCD        **1b**/**2b** = 0:100   **2b** (69%)
  6 ^\[d\],\ \[e\]^   **1c** (I, Bn)     CoCl~2~       TMCD        **1c**/**2c** = 0:100   **2c** (66%)
  7 ^\[d\]^           **1d** (Br, Boc)   CoCl~2~       TMCD        **1d**/**2a** = 0:100   **2a** (83%)

^\[a\]^ TMEDA = *N*,*N*-tetramethylethylenediamine, TMCD = (*R*,*R*)-tetramethylcyclohexanediamine. ^\[b\]^ The ratio was determined using the crude ^1^H-NMR spectrum. ^\[c\]^ Isolated yield. ^\[d\]^ Two equivalents of PhMgBr were added. ^\[e\]^ 50 mol % of TMCD were added.
